Skip to main content

Advertisement

Table 1 Characteristics of the patients a

From: Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes

Variables Number of patients (%)
All 9,415 (100)
Age at surgery, yr  
 <35 309 (3.3)
 35 to 50 3,809 (40.5)
 51 to 65 3,637 (38.6)
 >65 1,660 (17.6)
Menopausal status  
 Premenopausal 4,278 (45.4)
 Postmenopausal 5,137 (54.6)
Histological tumor subtype  
 Ductal 7,114 (75.6)
 Lobular 1,150 (12.2)
 Mixed 397 (4.2)
 Other 754 (8.0)
pT  
 pT1 6,601 (70.1)
 pT2 2,514 (26.7)
 pT3/4 300 (3.2)
pN  
 pNx 309 (3.3)
 pN0 5,201 (55.2)
 pN+ 3,905 (41.5)
Tumor grade  
 G1 2,160 (22.9)
 G2 4,930 (52.4)
 G3 2,007 (21.3)
 NA 318 (3.4)
ER positivity  
 ≥20% 9,228 (98.0)
 <20% 187 (2.0)
PgR positivity  
 ≥20% 6,758 (71.8)
 <20% 2,657 (28.2)
Ki-67 level  
 <14% 3,169 (33.7)
 14% to 19% 2,276 (24.2)
 ≥20% 3,970 (42.2)
PVI  
 Absent 7,039 (74.8)
 Present 2,376 (25.2)
Surgery  
 Quadrantectomy 7,777 (82.6)
 Mastectomy 1,638 (17.4)
Radiotherapy  
 No 1,416 (15.0)
 Yes 7,999 (85.0)
Chemotherapy  
 No 6,386 (67.8)
 Yes 3,029 (32.2)
Competing riskb  
 No events 7,149 (75.9)
 Locoregional relapse 592 (6.3)
 Distant metastasis 852 (9.0)
 Other 822 (8.7)
  1. aER, Estrogen receptor; NA, Not applicable; PgR, Progesterone receptor; pN, Pathologic node stage; pT, Pathologic tumor stage; PVI, Peritumoral vascular invasion. bDuring a median follow-up time, estimated in nonevents, of 8.1 years (IQR = 6.1 to 10.2 years).